Equities

Enfusion Inc

ENFN:NYQ

Enfusion Inc

Actions
TechnologyTechnology
  • Price (USD)10.10
  • Today's Change0.21 / 2.12%
  • Shares traded714.23k
  • 1 Year change+1.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform1
Hold3
Sell3
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Enfusion Inc have a median target of 9.82, with a high estimate of 11.00 and a low estimate of 8.50. The median estimate represents a -2.77% decrease from the last price of 10.10.
High8.9%11.00
Med-2.8%9.82
Low-15.8%8.50

Dividends in USD

Historical dividend information is not available for Enfusion Inc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Nov 04, 2024, Enfusion Inc reported 3rd quarter 2024 earnings of 0.05 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 3rd quarter results by 25.00%.
The next earnings announcement is expected on Mar 10, 2025.
Average growth rate+8.33%
Enfusion Inc reported annual 2023 earnings of 0.13 per share on Mar 12, 2024.
Average growth rate-4.24%
More ▼

Revenue history & estimates in USD

Enfusion Inc had 3rd quarter 2024 revenues of 51.17m. This missed the 51.66m consensus estimate of the 6 analysts following the company. This was 24.88% above the prior year's 3rd quarter results.
Average growth rate+3.61%
Enfusion Inc had revenues for the full year 2023 of 174.54m. This was 16.09% above the prior year's results.
Average growth rate+25.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.